NC
ICCC icon

Northpointe Capital’s ImmuCell ICCC Stock Holding History

Northpointe Capital’s Portfolio ICCC Stock Details ICCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-179,260
Closed -$1.39M – 194
2016
Q3 		$1.39M Sell
179,260
-74,242
-29% -$540K 0.14% 161
2016
Q2 		$1.75M Sell
253,502
-1,807
-0.7% -$12.2K 0.21% 155
2016
Q1 		$1.75M Buy
+255,309
New +$1.7M 0.22% 161

Other funds holding ICCC

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return
PCM
Perritt Capital Management Chicago, Illinois $59.8M AUM 26.94% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SRC
Shufro Rose & Co New York $1.47B AUM 19.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
EFS
Essex Financial Services Essex, Connecticut $1.78B AUM 23.37% 1-Year Est. Return
MA
Minerva Advisors Bala Cynwyd, Pennsylvania $155M AUM 35.49% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Northpointe Capital's ICCC Position: Q4 2016 in Review

Northpointe Capital sold out of ImmuCell (ICCC) in Q4 2016, closing a stake of 179,260 shares — an estimated $1.39M sold.

Northpointe Capital first reported a position in ICCC in Q1 2016 and held it in 3 quarters. The position peaked at $1.75M in Q2 2016. 16 funds tracked by Wall St. Rank hold ICCC as of Q4 2016.

  • Northpointe Capital reported no remaining ImmuCell position as of Q4 2016 after selling out during the quarter.
  • Northpointe Capital sold 179,260 ImmuCell shares in Q4 2016, an estimated $1.39M.
  • Northpointe Capital first reported a position in ImmuCell in Q1 2016 and held it in 3 quarters.
  • Northpointe Capital's ImmuCell position peaked at $1.75M in Q2 2016.
  • 16 funds tracked by Wall St. Rank held ImmuCell as of Q4 2016.

Based on Northpointe Capital's 13F filing for Q4 2016, filed 25 Jan 2017.